Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Cerebrovascular Diseases · doi:10.1159/000087203 · Cited by 410
RetractedWimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Manabe, S., Kuno, H., & Oizumi, K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.1.64 · Cited by 131
Retracted(2007) · Neurology · doi:10.1212/01.wnl.0000257089.50476.92 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetracted(2003) · Neurology · doi:10.1212/01.wnl.0000078892.24356.90 · Cited by 51
RetractedSato, Y., Kuno, H., Kaji, M., Saruwatari, N., & Oizumi, K. (1999) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199909000-00008 · Cited by 37
RetractedAnti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials
Zhong, Z., & Chen, J. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00007 · Cited by 30 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI · Paper page
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
Items 401–500 of 741
Lucassen, M. J. J., ter Wee, M. M., den Uyl, D., Konijn, N. P. C., Nurmohamed, M. T., Voskuyl, A. E., van Schaardenburg, D., Kerstens, P. J. S. M., Bultink, I. E. M., Boers, M., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05781-7 · Cited by 6
Yao, S. (2021) · Frontiers in Medical Science Research · doi:10.25236/fmsr.2021.030106 · Cited by 6
Calcium prescription by Indian orthopaedic surgeons: A survey and a review of literature
Sheth, B. A., Prabhakar, A., Pawar, P., Ganwir, H. P., Panchal, S., & Jain, A. (2021) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2021.02.015 · Cited by 6
Effects of BMP-2 compound with fibrin on osteoporotic vertebral fracture healing in rats.
Ouyang, X., Ding, Y., Li, Y., Xin, F., Yang, X., Sha, P., Tong, S., Cheng, Q., & Xu, Y. (2021) · PubMed Central · Cited by 6
Zhang, R., Mao, J., Wang, X., Nie, M., Ma, W., Ji, W., Yu, B., Huang, Q., & Wu, X. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.05.004 · Cited by 6
Zhu, H., Chen, H., Ding, D., Wang, S., Dai, X., & Zhu, Y. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/2909454 · Cited by 6
RetractedA meta-analysis of dietary inflammatory index and bone health status
Taheri, E., Mahdavi‐Gorabi, A., Moludi, J., Asayesh, H., & Qorbani, M. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00945-6 · Cited by 6
“Introduction Osteoporosis is an age-related metabolic bone disease characterized by bone mass reduction and alteration of bone architecture, which is the main risk factor of bone fragility and fracture [1].”
BackgroundKong, Y., Zhou, L., Liao, S., Wang, C., Chen, J., Cai, X., Zhao, S., Song, D., & Zhang, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.136516 · Cited by 6
Jia, Y., Qi, X., Ma, M., Cheng, S., Cheng, B., Liang, C., Guo, X., & Zhang, F. (2023) · Bone and Joint Research · doi:10.1302/2046-3758.122.bjr-2022-0206.r1 · Cited by 6
Rethinking of osteoporosis through a sex- and gender-informed approach in the COVID-19 era
VIOLI, A., FORTUNATO, V., D’Amuri, A., Zuliani, G., Basili, S., Passaro, A., Corica, B., & Raparelli, V. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.04893-4 · Cited by 6
Yoshida, T., Wang, J., & Stern, P. H. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_327 · Cited by 6
Patterns of menopausal hormone therapy use and hyperkyphosis in older women
Woods, G. N., Huang, M.-H., Cawthon, P. M., McDaniels-Davidson, C. R., Fink, H. A., & Kado, D. M. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001070 · Cited by 6
Giampà, E., Bonito, M. D., Ferretti, V., Nuvoli, G., Paoletti, F., Piazzini, M., Ranieri, M., Tuveri, M. A., & Vinicola, V. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03052-9 · Cited by 6
other members of the Technical Working Group, Gimigliano, F., Liguori, S., Moretti, A., Toro, G., Rauch, A., Négrini, S., & Iolascon, G. (2021) · Journal of Orthopaedics and Traumatology · doi:10.1186/s10195-021-00566-y · Cited by 6
Computer-Aided Systematic Review Screening Comes of Age
Hemens, B. J., & Iorio, A. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1295 · Cited by 5
Ibrahim, M. O., Kolleri, A., & Ginawi, A. (2023) · International Journal of Rheumatology · doi:10.1155/2023/2160346 · Cited by 5
“Furthermore, fi nally, the American College of Physicians (ACP) advises against monitoring throughout treatment because many women who receive antiresorptive medication experience a reduction in fractures even if their BMD does not improve [51].”
BackgroundPan, X., Liu, S., Chen, B. Z., Yu, Z., Wang, H. E., Tang, X., & Qin, Y. (2024) · BMC Public Health · doi:10.1186/s12889-024-20179-4 · Cited by 5
Azarfarin, M., Shahla, M. M., Mohaddes, G., & Dadkhah, M. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2024.39 · Cited by 5
Moura, S. R., Olesen, J. B., Lindberg‐Larsen, M., Barbosa, M. A., Søe, K., & Almeida, M. I. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02324-7 · Cited by 5
Multidisciplinary consensus on the management of patients with osteopenia and fracture risk in Spain
Úbeda, J. L. B., Díaz, S. G., Martínez, J. C. G., Martínez, N., Micó-Pérez, R. M., Möller, I., Neyro, J. L., Sáez-López, P., Santiñà, M., Vergés, J., et al. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-08997-y · Cited by 5
Burns, R. B., Smith, C. C., Shmerling, R. H., & Tess, A. V. (2018) · Annals of Internal Medicine · doi:10.7326/m18-2548 · Cited by 5
Pharmacotherapy: Sex and gender evidence in medication safety and efficacy
Sleeper, R. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00012-7 · Cited by 5
Reuman, L., Solar, C. A., MacLean, R. R., Halat, A. M., Rajeevan, H., Williams, D. A., Heapy, A. A., Bair, M. J., Krein, S. L., Kerns, R. D., et al. (2022) · Translational Behavioral Medicine · doi:10.1093/tbm/ibab165 · Cited by 5
Magdy, A., Fahmy, S. R., Mohamed, A. S., Saad, D. Y., Desokyand, R. S., & Baiomy, A. A. A. (2022) · International Journal of Morphology · doi:10.4067/s0717-95022022000100277 · Cited by 5
Analysis of clinical efficacy after PKP in patients of different genders
Yang, B. K., Zhao, Y., & Zhao, Y. (2022) · Medicine · doi:10.1097/md.0000000000031785 · Cited by 5
“[2] Unfortunately, bending and rolling over in everyday life can be a disaster for osteoporosis patients.[3,4] Due to the high frequency of spine movement and rapid bone loss, fractures caused by osteoporosis are mostly located in the spine.”
BackgroundKan, B., Hou, J., Leslie, W. D., Jiang, D., Zhang, J., & Yang, S. (2023) · Bone · doi:10.1016/j.bone.2023.116738 · Cited by 5
Clinical Considerations and Outcomes of Robotic Urologic Surgery in Obese Patients
Khater, N. P., Morris, A. G., VanValkenburg, D., Garcia, A. J., Jin, K., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2024) · Türk anesteziyoloji ve reanimasyon derneği dergisi · doi:10.4274/tjar.2023.231315 · Cited by 5
Zeng, W., Liu, W., Zhang, L., Zhang, Y., He, Y., Su, W., Huang, P., Huang, C., Lin, M., Li, X., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-024-01492-2 · Cited by 5
“In 2017, the latest clinical practice guidelines of the American College of Physicians pointed out that calcitonin is no longer widely used in the treatment of osteoporosis [23].”
Osteoporosis in neurological disorders: Parkinson’s disease, stroke, and multiple sclerosis
Oleson, C. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00041-1 · Cited by 5
Development and validation of a predictive model for spinal fracture risk in osteoporosis patients
Lin, X.-M., & Shi, Z. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i20.4824 · Cited by 5
Consensus document on osteoporosis in males
Varsavsky, M., Muñoz, M. R., Rubio, V. Á., Becerra, A., Martín, A. G., Diaz‐Guerra, G. M., Moreno, P. R., Gimeno, E. J., & Muñoz‐Torres, M. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.12.003 · Cited by 5
Sale, J. E. M., Gray, M., Mancuso, D., Inrig, T., Boire, G., Beaulieu, M., Funnell, L., & Bogoch, E. R. (2018) · Rheumatology International · doi:10.1007/s00296-018-4181-3 · Cited by 5
da Silva, V. C. R., Guerino, M. R., Rodrigues, F. T. M., Alves, K. F. P., de Lucena, L. C., Ferreira, A. P. D. L., & de Araújo, M. D. G. R. (2021) · Saúde e Pesquisa · doi:10.17765/2176-9206.2021v14n4e8806 · Cited by 5
Barriers and Resources to Optimize Bone Health in Orthopaedic Education
Levitt, E. B., Patch, D. A., Ponce, B. A., Razi, A. E., Kates, S. L., & Patt, J. C. (2021) · JBJS Open Access · doi:10.2106/jbjs.oa.21.00026 · Cited by 5
Bone Density Testing Is the Best Way to Monitor Osteoporosis Treatment
Rothman, M. S., Lewiecki, E. M., & Miller, P. D. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.05.044 · Cited by 5
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures
Qaseem, A., & Wilt, T. J. (2021) · Annals of Internal Medicine · doi:10.7326/l21-0434 · Cited by 5
Self-citationLara, I. P., Calzada‐Mendoza, C. C., Mera-Jiménez, E., López, E. R., Espinoza, J. L. A., Parra‐Barrera, A., & Gutiérrez-Iglesias, G. (2025) · Journal of Medicinal Food · doi:10.1089/jmf.2024.0256 · Cited by 4
Adolescent Body Mass Index, Weight Trajectories to Adulthood, and Osteoporosis Risk
Simchoni, M., Landau, R., Derazne, E., Pinhas‐Hamiel, O., Nakhleh, A., Goldshtein, I., Tsur, A. M., Afek, A. B., Chodick, G., Tripto‐Shkolnik, L., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.25079 · Cited by 5
Lengyel, B., Armos, R., Bojtor, B., Kiss, A., Tóbiás, B., Pikó, H., Illés, A., Horvath, E. M., Putz, Z., Takács, I., et al. (2025) · Pharmaceuticals · doi:10.3390/ph19010054 · Cited by 4
“[19,34,42,45,46,52,53,58,64,75,76,85,87,89, 91,92,103,119,120,129,131,133–135,137”
Cipolloni, V., Bonifacio, M., Hassny, S. M., Melara, G., Lucchetti, L., Gentile, M., & Conforti, A. (2026) · Medicina · doi:10.3390/medicina62040687 · Cited by 4
“Hip fractures are especially serious because they are associated with loss of independence, excess morbidity, and high one-year mortality [4,5].”
Xu, F., Wang, Y., & Zhu, X. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.010 · Cited by 4
Sheng, O. C., Wu, W., Peng, C.-H., Yao, T.-K., Chen, I., Wang, J., & Yeh, K. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-07373-6 · Cited by 4
Wu, H., Zhu, J., Yu, G., & Yu, L. (2024) · PubMed Central · Cited by 4
Lin, Q., Ouyang, X., Pan, Q., Huang, J., Zhang, Z., Yang, Y., Wang, H., Yang, L., Zhu, X., Li, X., et al. (2024) · Planta Medica · doi:10.1055/a-2462-4844 · Cited by 4
“Current drugs used for OP have remarkable efficacy [14], but some limitations exist, including poor tolerability and significant adverse effects [15,16].”
Zhao, C., Wu, F., Zhao, L., Zhong, J., Huang, C., Jiang, Z., Zheng, J., Yang, S., Zhang, C., & Zhang, L. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.10.284 · Cited by 5
An initial study of core muscles using ultrasound in postmenopausal women with osteoporosis
Luo, Y., Yue, W., Li, Z., Chen, L., Wang, P., & Sun, K. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-314 · Cited by 4
Enhancing Osteoporosis Efforts Through Lifestyle Modifications and Goal-setting Techniques
Prah, A., Richards, E. A., Griggs, R. R., & Simpson, V. (2017) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2017.07.015 · Cited by 4
Consensus Guidelines for the Treatment of Osteoporosis
Paci, M., Burks, S., & Wang, M. Y. (2017) · Neurosurgery · doi:10.1093/neuros/nyx530 · Cited by 4
Hagino, H., Sakai, A., Ikeda, S., Imanishi, Y., Tsurukami, H., Nakajo, S., & Miyakoshi, N. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01005-z · Cited by 4
Saving bones without risking brain—bisphosphonates and risk of stroke: matched case-control study
Asghar, Z. B., Caballero, A. G., Pathirannehelage, S., Williams, J., McKay, S. E., Grassby, P. F., de Lusignan, S., & Siriwardena, A. N. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05045-z · Cited by 4
Peptide‐Capped Mesoporous Nanoparticles: Toward a more Efficient Internalization of Alendronate
Añón, E., Costero, A. M., Amorós, P., Haskouri, J. E., Martínez‐Máñez, R., Parra, M., Gil, S., Gaviña, P., Terencio, M. C., & Alfonso, M. (2020) · ChemistrySelect · doi:10.1002/slct.202000417 · Cited by 4
Fang, P., Chen, Y., Chen, J.-L., Sun, J., Tan, J., Wang, R., & Wang, X. (2020) · Medicine · doi:10.1097/md.0000000000021811 · Cited by 4
“Another example, American College of Physicians guideline published in 2017 recommend that BMD monitoring should not be performed during the five-year medical treatment of osteoporosis in women.([19]) The Endocrine Society Guidelines published in 2020 recommend that postmenopausal women with low bone density and high…”
BackgroundBifunctional Role of CrkL during Bone Remodeling
Kim, J. H., Kim, K., Kim, I., Seong, S., Kook, H. Y., Kim, K. K., Koh, J., & Kim, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137007 · Cited by 4
Park, H. B., Son, S., Jung, J.-M., Lee, S. G., & Yoo, B. R. (2022) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2022.0028 · Cited by 4
Teng, M., Yuan, X. H., Wang, D., Gao, H., Zhang, K., Wang, W., & Zhao, B. (2022) · Stem Cells International · doi:10.1155/2022/1395299 · Cited by 4
“When the estrogen level decreases, the risk of bone fracture increases, as well as the bone density decreases and bone microstructure deteriorates [16].”
BackgroundRetractedPharmacological interventions for osteoporosis in people with chronic kidney disease stages 3-5D
Hara, T., Hijikata, Y., Matsubara, Y., & Watanabe, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013424 · Cited by 4
Jiang, Q., Zhang, F., Zhu, B., Zhang, H., Han, L., & Liu, X. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1294 · Cited by 4
“The resulting network model portrayed a picture of comparable outcomes in BMD change to select the optimum choice for PMO.”
BackgroundInfluentialMenopausal osteoporosis in the practice of a gynecologist
Kuznetsova, I. V., & Chilova, R. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-12-320-331 · Cited by 4
Moffatt, E. K., Wargo, R., Johnson, C., & Kawaguchi‐Suzuki, M. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1544 · Cited by 4
Medications, Therapeutic Modalities, and Regimens Used in the Management of Rheumatic Diseases
Moutsopoulos, H. Μ., & Zampeli, E. (2020) · Springer eBooks · doi:10.1007/978-3-030-56670-8_14 · Cited by 4
Diaz‐Guerra, G. M., Iglesias, S. G., & Miguel, G. A. (2018) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2018.06.019 · Cited by 4
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
Lewiecki, E. M. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0484 · Cited by 4
Mechanisms of Nontraditional and Lifestyle Interventions for Bone Health
Via, M. A., & Mechanick, J. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11269-3 · Cited by 4
Shibata, M., Okumura, M., Kawano, S., Hirotoshi, N. O. D. A., Toyota, C., & Mizuno, Y. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01429-8 · Cited by 3
Guo, J., Zhou, Z., Gong, J., Hu, W., & Liu, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1485095 · Cited by 3
León‐García, M., Martínez, E. C., Álvarez‐Pérez, Y., Pou, M. A., García‐Franco, A. L., Bas, A. S., Rodriguez‐Moreno, S., Delgado-Espinoza, C. E., Roca, P., Osuna, A. G., et al. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02966-z · Cited by 3
Chamass, S., Daher, L. A., & Itani, M. (2025) · IEEE Access · doi:10.1109/access.2025.3642471 · Cited by 3
“…as DXA are resource-intensive, large, costly, require rigorous quality control procedures, can produce inaccurate measurements in bones, lack reference indices (T score, Z score) for populations with large racial diversity, and expose patients to ionizing radiation [15], [16], [17], [18], [19].”
Zhao, W., Deng, W., Wang, Y., Zhu, R., Liu, J., Chen, H., Tang, W., Luo, Y., Du, A., Zhu, H., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117678 · Cited by 3
Chao, W.-C., Chen, Y.-H., Shih, J.-C., Cheng, B., & Ml, H. (2026) · Osteoporosis International · doi:10.1007/s00198-025-07823-4 · Cited by 3
Unlocking bone repair in osteoporosis by targeting the angiogenic niche
Chen, M., Wang, J., Wei, J., & Feng, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1790054 · Cited by 3
Coexistence of Osteomalacia in Osteoporotic Hip Fractures in More Than 50 Years Age Group
Kumar, K., Bhayana, H., Vaiphei, K., Chouhan, D. K., Kanojia, R. K., & Bhadada, S. K. (2021) · Indian Journal of Orthopaedics · doi:10.1007/s43465-020-00323-z · Cited by 3
Musculoskeletal Health in Menopause
Geier, K. A., & Benham, A. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-85484-3_13 · Cited by 3
Does osteoporosis cause pain even without a fracture? An observational study
Okçu, M., Erden, Y., Tuncay, F., Koçak, F. A., Kaya, S. S., & DOĞRU, Y. G. (2023) · Somatosensory & Motor Research · doi:10.1080/08990220.2023.2188929 · Cited by 3
Yu, L., Xue, H., & Li, Z. (2024) · Neuroreport · doi:10.1097/wnr.0000000000001994 · Cited by 3
Review of recommendations for bisphosphonate treatment interruption-discontinuation
Fominykh, M. I., & Evstigneeva, L. P. (2024) · Osteoporosis and Bone Diseases · doi:10.14341/osteo13146 · Cited by 3
Maimaiti, Z., Li, Z. Y., Li, Z., Fu, J., Xu, C., Chen, J., Chai, W., & Liu, L. (2024) · Digital Health · doi:10.1177/20552076241269613 · Cited by 3
“35 It is worth mentioning that the authors used machine learning methods to update the guideline, which indicates that DHTs are gradually playing an essential role in developing and updating clinical guidelines.”
BackgroundMethodRevisão sobre fraturas osteoporóticas: Ocorrência, prevenção e consequências
Elias, N., Ribeiro, J. E. G., Campinho, L. A., Reis, C., Elias, L. A. M. S., & Labronici, P. J. (2025) · Revista Brasileira de Ortopedia · doi:10.1055/s-0045-1809515 · Cited by 3
Referenciamento e contrareferenciamento à Atenção Primária de à Saúde de idosos com osteoporose
Veloso, R. C. D. S. G., Pinheiro, F. C., NASCIMENTO, M. M. G. D., & Ruas, C. M. (2022) · Saúde (Santa Maria) · doi:10.5902/2236583469401 · Cited by 3
Miller, M. J., Jou, T., Danila, M. I., Mudano, A. S., Rahn, E. J., Outman, R. C., & Saag, K. G. (2020) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2020.09.010 · Cited by 3
Women’s health update: A literature review impacting primary care
Dolan, B. M., Merriam, S. B., Prifti, C. A., & Walsh, J. M. E. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21123 · Cited by 3
“27 Determining the continuation of bisphosphonate treatment after 5 years is complicated.”
Zuogui Wan alleviates ovariectomy-induced osteoporosis by maintaining FoxO3 and increasing NK1R
Li, X., Tan, F., Wu, D., Mai, C., Guan, H., & Fan, Q. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.10.28 · Cited by 3
Sun, X., Leder, B. Z., Bolster, M. B., Ly, T. V., Franco‐Garcia, E., Pu, C. T., & Fan, W. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae050 · Cited by 3
“Because the effect on the fracture risk reduction of vitamin D in combination with calcium is more consistent compared with that of vitamin D alone [19-21], all patients under MGH FLS care, regardless of 25OHD level, receive 650 to 1000 mg per day of elemental calcium with very rare exception [22].”
BackgroundDaidzein alleviates isoproterenol-induced cardiac injury in rats via NF-kB pathway inhibition
Ramachandran, V., Vaikunth, V., Mohanasundaram, T., Tıwarı, R., & Magesh, H. (2024) · Hacettepe University Journal of the Faculty of Pharmacy · doi:10.52794/hujpharm.1338923 · Cited by 3
Hari Raj, K., & Gnanavel, S. (2024) · Emergent Materials · doi:10.1007/s42247-024-00863-2 · Cited by 3
Long-term outcome of unilateral adrenalectomy for primary bilateral macronodular adrenal hyperplasia
Zhou, H., Yin, Y., Zhang, P., Li, B., Wang, Y., Lyu, Z., Gu, W., & Mu, Y. (2024) · Endocrine · doi:10.1007/s12020-024-04030-9 · Cited by 3
Medications, Therapeutic Modalities, and Regimens Used in the Management of Rheumatic Diseases
Moutsopoulos, H. Μ., Zampeli, E., & Vlachoyiannopoulos, P. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-71604-6_14 · Cited by 3
Huang, F., Zhao, S., Qiu, M., Li, Y., Zhan, X., Wu, C., Chushuo, S., Sun, W., Chen, G., & Xu, Y. (2019) · Medicine · doi:10.1097/md.0000000000015108 · Cited by 3
“Although these drugs have certain clinical curative effect,([3,6]) long-term use of them will have many side effects (such as a typical femoral subtrochanteric fractures, gastrointestinal side effects, hot flashes, thromboembolism events, and some drug-specific infections).”
BackgroundCórdova–Fraga, T., Hernández-González, M. A., Hernández-Rayas, A., & Ponce-Covarrubias, D. A. (2020) · Open Journal of Applied Sciences · doi:10.4236/ojapps.2020.105016 · Cited by 3
“This already has become a public health problem on a world level, with a 30% increase in morbidity and mortality and with an estimated economic impact around $25 trillion dollars per year [2].”
BackgroundImpact of heart failure severity on bone mineral density among older patients with heart failure
Kono, Y., Izawa, H., Aoyagi, Y., Yamada, R., Ishiguro, T., Yoshinaga, M., Okumura, S., Fujiwara, W., Hayashi, M., & Otaka, Y. (2021) · Heart and Vessels · doi:10.1007/s00380-021-01884-1 · Cited by 3
A influência da atividade física para a prevenção e tratamento da osteoporose: revisão integrativa
da Silva, B. B. L., Alves, A. K. R., Pereira, R. D. B., Rodrigues, S. L. G., Júnior, J. G. E. S., Nogueira, F. D., Alves, F. R. D. O., Veras, I. L., da Silveira, E. M. D. Q. F. B., Melo, L. G., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i11.19968 · Cited by 3
Luo, W., Zhang, J., Xu, L., Zhou, Y., Xu, D., Lv, Q., Xiao, Y., & Yang, Q. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051983 · Cited by 3
“Bisphosphonates (BPs) are potent selective inhibitors of osteoclastic bone resorption and are commonly used for treating osteoporosis [12,13].”
BackgroundKleinermans, D., Joyson, A., & Wray, H. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.957 · Cited by 3
Bringing Attention to Lesser-known Bone Remodeling Pathways
Shadmand, M., Jackson, K. L., Bender, C., Donnelly, S., Guan, H., Tobin, K., Oms, S. N. Y., Hum, J. M., & Lowery, J. W. (2018) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-018-9250-3 · Cited by 3
NEW APPROACHES TO OSTEOPOROSIS IN PRIMARY CARE
Universitatea de Medicină şi Farmacie “Carol Davila“, B., Baltă, M. D., Iancu, M. A., Universitatea de Medicină şi Farmacie “Carol Davila“, B., Matei, D. B., Universitatea de Medicină şi Farmacie “Carol Davila“, B., & Institutul Naţional pentru Sănătatea Mamei şi Copilului „Alessandrescu-Rusescu“, B. (2017) · Romanian Journal of Medical Practice · doi:10.37897/rjmp.2017.4.2 · Cited by 3
Llavero-Valero, M., Vaamonde, J., Martínez, S. B., & López‐Frías, M. (2018) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2018.11.023 · Cited by 3
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
Reginster, J., Rizzoli, R., Kanis, J. А., & Cooper, C. C. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0488 · Cited by 3
Correction: Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
(2017) · Annals of Internal Medicine · doi:10.7326/l17-0463 · Cited by 3
Launching the Emirates Osteoporosis Society (EOS) Guidelines 2022 in the United Arab Emirates
Izzi, M. A., Suhaili, A. A., El-Serafi, A. T., Abogamal, A. F., Tapponi, L., & Brodzinski, Z. (2023) · New Emirates Medical Journal · doi:10.2174/04666230126094059 · Cited by 2
Dietary intervention reprograms bone marrow cellular signaling in obese mice
Zheng, Y., Yan, J., Zhang, X., Cui, H., Wei, Z., Li, X., Wang, Q., & Zhong, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1171781 · Cited by 2
Badid, N., & Hadji, F. (2023) · Electronic physician · doi:10.26415/2008-5842-vol15iss1p7917-7925 · Cited by 2
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.